Abiomed Recalls Impella 5.5 Left Ventricular Device Systems: Urgent Action Required to Address Product Leakage

Recall Alert: Abiomed Addresses Product Leakage in Impella 5.5 Left Ventricular Device Systems

In a recent announcement, medical technology company Abiomed disclosed a recall for specific left ventricular assist device sets used in patients with cardiomyopathy. The recall was prompted by customer complaints regarding purge fluid leakage from the sidearm of the pump, raising concerns about potential risks to patient safety. The U.S. Food and Drug Administration (FDA) has classified this recall as a class I recall, signifying the most severe level of risk associated with the use of these devices.

Scope and Impact of the Recall

The recall specifically affects Impella 5.5 with SmartAssist systems that were distributed between September 28, 2021, and March 6, 2023. These systems are utilized for up to 14 days in cases of ongoing cardiogenic shock, occurring within 48 hours after an acute myocardial infarction (MI), open-heart surgery, or due to cardiomyopathy. The class I designation emphasizes that the use of these devices may result in serious injuries or even death.

It’s important to note that the latest versions of the Impella 5.5 with SmartAssist sets, featuring a preinstalled sidearm retainer and a new yellow luer, are not subject to the recall, according to Johnson & Johnson, the parent company of Abiomed.

Potential Risks and Consequences

The leakage of purge fluid poses significant risks to patients relying on the Impella 5.5 left ventricular device system. When a purge leak occurs, the system experiences low purge pressures, triggering alarms and necessitating immediate evaluation. If the leakage issue remains unresolved, persistently low purge pressure and purge flow can lead to pump stoppage, resulting in the loss of therapy. This failure in the pump’s support system can have severe consequences for critically ill patients, exacerbating their condition and potentially leading to serious injury or death. The FDA has emphasized the criticality of addressing this issue promptly to mitigate the risks faced by patients.

Recall Details and Response

Abiomed has reported a total of 179 complaints associated with the recalled devices. While three injuries have been reported, no deaths have been linked to the recall at this time. Recognizing the urgency of the situation, the company has sent an urgent medical device recall letter to its customers, urging immediate action to address the product leakage.

For further information or inquiries regarding the recall, customers are advised to contact Abiomed’s clinical support center at 800-422-8666. The company’s swift response and commitment to resolving the issue demonstrate their dedication to patient safety and ensuring the efficacy of their medical devices.

In conclusion, the recall of specific Impella 5.5 left ventricular device systems by Abiomed highlights the critical importance of addressing product leakage promptly. This urgent action is necessary to protect patients with cardiomyopathy from potential harm or adverse events. By raising awareness of this recall and taking the necessary precautions, healthcare professionals can ensure patient safety and prevent further injuries.